🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Armata Pharmaceuticals, Inc. ARMP PHARMA

Healthcare · Biotechnology · United States
https://www.armatapharma.com
Company Profile ↓
$5.82
+132.80% 1Y
Mkt Cap$216.40M
P/E-1.10
P/B-0.87
52W High$14.80
52W Low$2.43
Book Value$-6.22
EPS (TTM)$-5.29

Company Overview

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 79.5%, reflecting efficient use of shareholder capital.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue +15.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-
1 Year:15.70%

Stock Price Performance

1 Year:+132.80%
6 Months:-49.87%
3 Months:-23.12%
1 Month:+23.57%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 27% of range
$2.43 $14.80
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)60.10 · Neutral
Price Performance
1M+23.57%
3M-23.12%
6M-49.87%
1Y+132.80%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 79.5%.

CONS

  • Trading 60.7% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-1.10
Industry PE
24.83
Forward P/E
-3.03
PEG Ratio
-
Book Value
$-6.22
Price to Book
-0.87
P/S
36.29
EV/EBITDA
-15.14
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
15.70%
Earnings (YoY)
-

Profitability & Returns

ROCE
-53.93%
ROE
79.51%
ROA
-25.83%
Profit Margin
0.00%
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-3.16
EPS (TTM)
$-5.29

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
0.11
Current Ratio
0.11
Debt
$313.95M
Total Assets
$69.80M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
67.64%
Chg in Prom Hold
-0.87%
FII / Inst Holding
13.45%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
$216.40M
Total Revenue (TTM)
$5.54M
EBITDA
$-33.45M
Free Cash Flow
$-27.41M
Operating Cash Flow
$-25.42M
Shares Outstanding
37.18M
Gross Margin
-
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ARMP Armata Pharmaceuticals, Inc. PHARMA 5.82 -1.10 $216.40M 0.00% -53.93% 79.51% - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2014Jun 2014Sep 2014Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue ----------------------31.00K-----------------
Operating Income -2.53M-3.75M-5.23M-2.60M-2.27M-2.59M-2.43M-2.94M-4.52M-3.59M-3.41M-11.86M-3.36M-9.69M-746.00K-3.06M-2.84M-2.43M-3.44M-5.16M-6.78M-4.92M-4.59M-5.62M-5.43M-6.20M-6.14M-8.78M-9.22M-8.62M-11.35M-9.63M-10.34M-10.23M-11.91M-9.76M-8.19M-6.84M-7.78M-8.79M
Net Income -11.31M13.87M21.21M-664.00K-14.49M10.77M5.44M-2.23M-3.11M-3.85M-2.38M-9.50M-3.25M-6.46M-779.00K-3.13M-3.17M-2.77M-3.74M-4.20M-6.96M-5.08M-4.71M-5.77M-5.50M-6.19M-5.42M-8.77M-9.21M-8.61M-14.49M-3.55M-31.16M-25.02M8.99M-5.48M-6.53M-16.30M-26.68M-115.35M
Diluted EPS -3.18-0.63-0.86-0.44-3.49-0.33-0.30-0.54-0.82-7.82-3.23-0.76--1.46-0.09-0.24-0.68-0.60-0.11-0.69-0.73--0.26-0.31-0.27-0.25-0.22-0.30-0.26-0.24-0.40-0.17-0.86-0.69-0.25-0.15-0.20-0.45-0.74-3.16
R&D Expense 1.01M1.89M1.79M-972.00K1.08M728.00K-1.98M1.24M1.66M-1.49M1.13M-1.46M1.69M361.00K1.49M---------------------

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Income -12.38M-14.11M-10.23M-23.38M-16.16M-17.66M-19.75M-21.59M-23.82M-36.95M-40.89M-42.44M-36.63M
Net Income -64.58M23.11M-516.00K-18.84M-12.84M-16.70M-19.48M-22.18M-23.16M-36.92M-69.05M-18.92M-173.80M
Diluted EPS -0.64-2.33-1.99-24.67-2.18-3.59-2.55-1.35-0.96-1.08-1.91-0.89-4.80
R&D Expense 6.47M5.80M3.99M5.68M2.88M8.37M9.82M------

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -41.21M28.62M31.49M18.15M11.14M14.54M25.45M39.52M69.77M95.83M98.36M86.44M76.88M
Total Equity 12.94M-22.62M3.44M12.71M9.72M24.34M7.69M14.59M18.86M25.40M36.08M-32.06M-48.02M-218.60M
Cash & Equivalents 862.00K20.36M6.58M9.37M5.71M5.13M9.66M6.03M9.65M10.29M14.85M13.52M9.29M8.69M
Total Liabilities -63.13M23.19M6.89M8.43M3.41M6.85M10.86M20.66M44.37M59.75M130.43M134.46M295.48M
Current Liabilities -2.39M1.87M2.38M3.54M1.97M2.03M4.88M6.71M4.81M24.87M16.46M48.25M8.95M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ----10.61M-9.19M-10.63M-15.58M-18.27M-23.57M-32.48M-47.42M-37.55M-25.76M
Investing Cash Flow ----279.00K-58.00K8.81M2.88M-824.00K-1.30M-2.21M-8.13M-1.88M-542.00K
Financing Cash Flow ---7.23M8.67M12.45M8.97M23.21M25.52M44.02M53.99M34.96M25.61M
Capital Expenditure -102.00K-1.20M-210.00K-279.00K-58.00K-875.00K-224.00K-824.00K-1.30M-2.21M-8.14M-1.88M-542.00K
Free Cash Flow ----10.88M-9.25M-11.50M-15.81M-19.09M-24.88M-34.69M-55.57M-39.43M-26.30M
Dividends Paid ---80.00K---------

Ratios (Annual)

Figures in %.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------
Operating Margin % -------------
Net Margin % -------------
ROE % 285.4%672.4%-4.1%-193.7%-52.7%-217.1%-133.5%-117.6%-91.2%-102.3%215.3%39.4%79.5%
ROCE % -31.9%-52.7%-35.1%-160.0%-176.2%-141.1%-96.0%-65.8%-36.7%-52.1%-49.9%-111.1%-53.9%

Shareholding Pattern

Insiders
67.64%
Institutions
13.45%
Public Float
41.58%

Top Institutional Holders

#Holder% HeldSharesValue
1 Madison Asset Management, LLC 5.67% 2.11M $8.81M
2 Blackrock Inc. 1.51% 559.99K $2.34M
3 Vanguard Capital Management LLC 1.31% 487.97K $2.04M
4 Millennium Management Llc 1.27% 470.50K $1.97M
5 Geode Capital Management, LLC 0.73% 270.55K $1.13M
6 Dauntless Investment Group, LLC 0.55% 203.89K $852.26K
7 State Street Corporation 0.35% 129.60K $541.73K
8 Northern Trust Corporation 0.24% 89.79K $375.33K
9 Vanguard Portfolio Management LLC 0.22% 81.35K $340.06K
10 Edgewood Management Llc 0.22% 80.00K $334.40K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ARMP

Google News Fri, 04 Sep 2026

Armata Pharmaceuticals Stock Price Forecast. Should You Buy ARMP? - StockInvest.us

<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE9tT3U5eDE5QTQxUDRvbkZsNWktblJQd0VKLUpHZWZhUkVtTG9GVGwyZXhSUlNkRlFjeVRBSmNzWUt5QlROcXBtaw?oc=5" target="_blank">Armata Pharmaceuticals Stock Price Forecast. Should You Buy ARMP?</a>…

Google News ue, 21 Jul 2026

Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQWU5obFEybnoyeU11SWxYV2oxanhXRzBGcVM5Uk9OSEFwd25TNFVIQ0Q2RVlTVHk2akRVSTFLSmU2c1dOaXc2N1pMeW9hUmtKMGVUTXgtenJvRXdtSHVzanRLdE1UVFZGd2lOa3cwRU1xdDN3bXpWUF9tcG5GakM4eHZSd3ZmdnNGem1Val…

Google News hu, 03 Sep 2026

A newly identified protein helps a bacteria-targeting virus deliver genes - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxORVR3b1RlZWwyektRaXNCWUF4VWJraE00TUNTbWtFd3FGWl90T2xVQTNUOEVNcUozM0hkREh1SW1KZzN4OVVOODZ5MzM0S2FOUDFxcnBlN3o3R21xZlhyYlhYa0ctVTV4anJIYndvWFlpeUYwMDRiWXZha0FxSU5GdDJSUVRXTXF5N3I1NH…

Google News Sun, 06 Sep 2026

Why (ARMP) Price Action Is Critical for Tactical Trading - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOWS1SVUc5VkhKYkZoVGlHVExHd3d5M19LVXlSdlBxdDZ6b0lvdjlYRHAwOVlLTjFXOTZBRHItaVk3bUNZYlF6UE5MQXNhaDJjcE4yb2RmNERrdHhSQnBSWDVzRXByQ09rR2VxOHdKbVdlekp4QS1oX2RHYTI2SUNud2laM1l1ZlBHUVpDRm…

Google News Fri, 26 Jun 2026

ARMP Forecast — Price Target — Prediction for 2027 - tradingview.com

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFBvMEVTT2h0X2hyVFA2b0ozM29obnJmNzRaSGZZb3N3dDlOQ0F6S1NfU1BhejVYRThVbUJINmlKUVBCRVBSSmEtZHpuOWhtczQzQXRFcVhUbjNhSkNsOUVVcFdRTHZtR203b2hnQXBMM2JhZHY5VnFz?oc=5" target="_blank">ARMP Fo…

Google News Fri, 19 Jun 2026

Here’s Why Armata Pharmaceuticals Inc. (ARMP) is a High Growth Micro-Cap Stock to Buy? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNU2psN1BLWWdFWk16YVp5Y1dTSWZoMTEwXzA5TjZ0MU5RRnc5NURYZjZRU25BRDJ0RVpaNTdadEQ2bG1DUHNNaTJrT0ttUlBsWGtkYkEyTkZyN3NxcEtNdmkwVEZDQlo3V2hMb0R6bFdYaWJHdUJXREJvNUctaFc0dG9iM0p1NGt3V1RITE…

ARMP — Frequently Asked Questions

What is the current share price of Armata Pharmaceuticals, Inc. (ARMP)?

As of 2026-09-19 21:16 PDT, Armata Pharmaceuticals, Inc. (ARMP) trades at $5.82 on NYSE American. Its 52-week range is $2.43 to $14.80.

What is the market capitalisation of ARMP?

Armata Pharmaceuticals, Inc. (ARMP) has a market capitalisation of $216.40M on NYSE American.

What is the P/E ratio of ARMP?

ARMP trades at a trailing price-to-earnings (P/E) ratio of -1.10. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.87.

What is the return on equity (ROE) of ARMP?

ARMP has a return on equity (ROE) of 79.51%. Its return on capital employed (ROCE) is -53.93%.

Is ARMP a good stock to buy?

This page provides a data-driven analysis of Armata Pharmaceuticals, Inc. (ARMP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space